METHOD FOR DIAGNOSING SECONDARY NEPHROPATHIES IN RHEUMATIC DISEASES IN CHILDREN Russian patent published in 2024 - IPC G01N33/68 C12Q1/6858 G01N33/564 G01N33/573 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to clinical nephrology, and can be used for diagnosis of secondary nephropathies accompanying rheumatic diseases in children. Enzyme immunoassay is used to determine the level of endothelial dysfunction markers and growth factors: endothelin-1 in blood and urine, a transforming growth factor β in blood and urine, homocysteine in urine, genotypes of folate cycle genes are determined: methylenetetrahydrofolate reductase MTHFR A1298C, methionine synthase MTR A2756G, methionine synthase reductase MTRR A66G. When determining the level of at least one of the markers in said ranges: endothelin-1 in serum 264.5–322.49 pg/ml, in urine 20.5–36.2 pg/ml; transforming growth factor β in serum 53.7–97.57 pg/ml, in urine 69.9–143.17 pg/ml; urine homocysteine is 399.8-1,500.6 ng/ml, and the presence of at least one of the pathological genotypes is determined: CC – MTHFR A1298C, GG – MTR A2756G, GG – MTRR A66G, secondary nephropathies are diagnosed in children with rheumatic diseases.

EFFECT: method enables the informative diagnosis of secondary nephropathies in children with rheumatic diseases by assessing a complex of endothelial dysfunction indicators: endothelin-1, homocysteine, transforming growth factor β taking into account genetic predisposition: polymorphisms of folate cycle genes MTR A2756G, MTHFR A1298C, MTRR A66G.

1 cl, 2 tbl, 4 ex